Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/EJE-09-0068
European Journal of Endocrinology, Vol 161, Issue 1, 141-152
Copyright © 2009 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Files
Right arrow All Versions of this Article:
EJE-09-0068v1
161/1/141    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laurell, C.
Right arrow Articles by Bäckdahl, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laurell, C.
Right arrow Articles by Bäckdahl, M.

CLINICAL STUDY

Transcriptional profiling enables molecular classification of adrenocortical tumours

Cecilia Laurell*, David Velázquez-Fernández1,*, Kristina Lindsten2, Christofer Juhlin1, Ulla Enberg1, Janos Geli1, Anders Höög3, Magnus Kjellman1, Joakim Lundeberg, Bertil Hamberger1, Catharina Larsson1, Peter Nilsson and Martin Bäckdahl1

School of Biotechnology, KTH-Royal Institute of Technology, 11427 Stockholm, Sweden, Departments of1 Molecular Medicine and Surgery2 , Cell and Molecular Biology3 Oncology-Pathology, Karolinska Institutet, 17176 Stockholm, Sweden

(Correspondence should be addressed to C Laurell; Email: claurell{at}kth.se)

* (C Laurell and D Velázquez-Fernández contributed equally to this work)

Objective: Tumours in the adrenocortex are common human tumours. Malignancy is however, rare, the yearly incidence being 0.5–2 per million inhabitants, but associated with a very aggressive behaviour. Adrenocortical tumours are often associated with altered hormone production with a variety of clinical symptoms. The aggressiveness of carcinomas together with the high frequency of adenomas calls for a deeper understanding of the underlying biological mechanisms and an improvement of the diagnostic possibilities.

Methods: Microarray gene expression analysis was performed in tumours of adrenocortex with emphasis on malignancy as well as hormonal activity. The sample set consisted of 17 adenomas, 11 carcinomas and 4 histological normal adrenocortexes. RNA from these was hybridised according to a reference design on microarrays harbouring 29 760 human cDNA clones. Confirmation was performed with quantitative real time-PCR and western blot analysis.

Results: Unsupervised clustering to reveal relationships between samples based on the entire gene expression profile resulted in two subclusters; carcinomas and non-cancer specimens. A large number of genes were accordingly found to be differentially expressed comparing carcinomas to adenomas. Among these were IGF2, FGFR1 and FGFR4 in growth factor signalling the most predominant and also the USP4, UBE2C and UFD1L in the ubiquitin-proteasome pathway. Moreover, two subgroups of carcinomas were identified with different survival outcome, suggesting that survival prediction can be made on the basis of gene expression profiles. Regarding adenomas with aldosterone overproduction, OSBP and VEGFB were among the most up-regulated genes compared with the other samples.

Conclusions: Adrenocortical carcinomas are associated with a distinct molecular signature apparent in their gene expression profiles. Differentially expressed genes were identified associated with malignancy, survival as well as hormonal activity providing a resource of candidate genes for an exploration of possible drug targets and diagnostic and prognostic markers.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 European Society of Endocrinology.